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in a hypothetical ten-million member health plan over a 3-year horizon. Estimates 
of plan cancer rates and utilization of HEC and MEC therapies were derived from 
epidemiological and market data. Treatment costs were computed using standard 
prescribing dosages, U.S. drug cost listings and simple reimbursement and dis-
pensing assumptions. Uptake of NEPA was calculated at 5% a year for 3 years, and 
competing antiemetic therapies were reduced proportionately based on initial share 
assumptions. RESULTS: A total of 54,000 patients with cancer were identified in the 
model scenario. Of these, 9,882 (18.3%) would receive HEC and 3,949 (7.3%) would 
receive MEC requiring combination therapy, for a total of 13,830 eligible for NEPA. 
Cost of CINV prevention prior to the adoption of NEPA was estimated at $40.96 mil-
lion. Following adoption of NEPA, cumulative costs were reduced by nearly $652K by 
the end of year 3. Calculations using PMPM estimates showed cumulative savings 
of $0.002 in year 1, $0.004 in year 2, and $0.005 in year 3. CONCLUSIONS: Results of 
the model indicate that adoption of NEPA for the prevention of CINV may have a 
relatively neutral impact on a U.S. health plan budget. Additionally, these estimates 
do not include savings from a potential reduction in the overall rate of CINV.
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OBJECTIVES: To evaluate the cost of lung cancer treatment in Brazil from the 
perspective of private hospitals and identify the major cost drivers. METHODS: 
Orizon administrative claims database containing over 18 million lives was used 
to identify patients with lung cancer using the following ICD-10 codes: C34, C34.9, 
C34.0, C34.1, C34.3, C34.8, C34.2 between the period of November 2010 to October 
2013. Only patients receiving traditional chemotherapy for their lung cancer were 
included in the analysis. RESULTS: A total of 11,348 patients were identified with 
lung cancer over the analysis period. The study population was 54% men, 62 years 
old on average, and received treatment for a mean duration of 5,5 months. Of the 
11,348 patients, 3,076 were hospitalized and 8,272 received outpatient care. Forty-
nine percent of those hospitalized also received outpatient care. For patients who 
were hospitalized, each patient had, on average, 4.63 hospitalizations with an aver-
age length of stay of 9.55 days. The average cost per patient hospitalized was BRL 
34,904, with approximately 25.67% of the total hospital cost spent on drugs and the 
remainder spent on fees, supplies, exams and procedures (24.41%, 37.31%, 5.71% 
and 6.89% respectively). For outpatient care, the average cost per patient was BRL 
22,746 with 87.61% of the total outpatient care cost spent on drug expenses and 
the remainder spent on fees, supplies, exams, and procedures (1.73%, 4.02%, 3.76% 
and 2.88% respectively). CONCLUSIONS: The economic burden of lung cancer in 
Brazil could be reduced especially in outpatient care if oral treatments instead of 
infusion-based treatments were used (e.g., avoidance of infusion-related resources 
such as fees, procedures and supplies), which could represent a reduction of 8.63% 
or BRL 1,956 per lung cancer patient.
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OBJECTIVES: Clinical research has demonstrated that laparoscopic liver resec-
tion for hepatocellular carcinoma or secondary colorectal metastases provides 
oncologically equivalent patient outcomes when compared to open liver resection, 
while also providing a statistically significant reduction in postoperative complica-
tions. Approximately 16% of all liver resections in Canada are performed lapras-
copically with a compound annual growth rate of 16%. In the Canadian healthcare 
environment hospitals face constrained budgets and it is critical to demonstrate 
the impact of laparoscopic liver resection to increase procedure volume. This 
study was conducted to determine the budget impact of increasing the propor-
tion of laparoscopic vs. open liver resection in a Canadian hospital. METHODS: 
We examined the budget impact of increasing the percentage of laparoscopic liver 
cases from 16% to 40%, while decreasing the number of open cases proportion-
ately in a hospital that performs 50 resections annually. The model incorporates 
the costs associated with surgery, length of stay (taking into account facility and 
staff costs) and postoperative complications. The cost data used in the model 
was obtained from peer reviewed literature, the Ontario Case Costing Initiative 
and costing data from a large Canadian hospital. Data on patient outcomes was 
obtained from published meta-analyses. A multivariate sensitivity analysis using 
a Monte Carlo simulation was completed to ensure scientific rigour. RESULTS: 
Laparoscopic liver resections are associated with higher device costs, but similar 
overall procedure costs. The additional device cost is offset by a shorter length of 
stay and lower rate of post-operative complications. The model establishes that 
for a Canadian hospital performing 50 liver resections increasing the proportion 
of laparoscopic cases from 16% to 40% allows for a potential cost savings of CAD 
$50,730 annually. CONCLUSIONS: In a Canadian hospital, laparoscopic liver resec-
tion is a more cost-effective procedure for hepatocellular carcinoma or secondary 
colorectal metastases when compared to open resection.
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OBJECTIVES: Estimate the annual economic impact of the introduction of axitinib as 
a therapy for metastatic renal cell carcinoma (mRCC) in the budget of the Ministry 
0.50, p= 0.004), 12 (HR: 0.60, p= 0.009), and 18 (HR: 0.58, p= 0.002) months compared 
to patients receiving 1st-line chemo (patients with known site of metastases: 0.51 
[p= 0.031], 0.61 [p= 0.049], and 0.63 [p= 0.045], respectively) after adjusting for patient 
characteristics. CONCLUSIONS: Compared to chemotherapy, early endocrine ther-
apy may be associated with better survival in postmenopausal women with HR+/
HER2- mBC after adjusting for patient characteristics.
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OBJECTIVES: In oncology trials, it is common practice to offer patients the possibility 
to switch from their randomized treatment to another active treatment upon dis-
ease progression. When patients switch to, and benefit from, active post-progression 
therapies which do not form part of the standard treatment pathway, a standard 
intention-to-treat (ITT) analysis may inaccurately estimate the ‘‘true’’ overall survival 
(OS) benefit associated with the investigational product [Latimer et al, 2014]. Using 
published data from the interim analysis of the PREVAIL study [Beer et al, 2014], 
we estimated the effects of enzalutamide compared to placebo on OS, adjusting for 
the potential confounding effects of switching to antineoplastic therapies that do 
not form part of the standard mCRPC treatment pathway in the UK. METHODS: 
Published treatment switching adjustment methods were applied including the 
Inverse Probability of Censoring Weights (IPCW) and a two-stage accelerated failure 
time model. The suitability of each method was evaluated by examining the study 
characteristics, the treatment switching mechanism, and by assessing the plausi-
bility of the underlying assumptions of the models in the context of the PREVAIL 
study. RESULTS: Overall, 180/845 (21%) patients in the placebo arm and 129/872 (15%) 
patients in the enzalutamide arm of PREVAIL switched to non-standard antineoplastic 
therapies. The unadjusted ITT analysis for OS resulted in a hazard ratio (HR) of 0.706 
(95% CI: 0.595 - 0.837) for enzalutamide compared to placebo, which was reduced 
to 0.662 (95% CI: 0.568 -0.809) using the two-stage method with no recensoring and 
0.625 (95% CI: 0.517 - 0.752) using the IPCW method. CONCLUSIONS: Adjusting for 
non-standard subsequent therapies given in PREVAIL resulted in a larger estimated 
treatment effect on OS associated with enzalutamide. This suggests that receipt of 
non-standard subsequent antineoplastic therapies caused the ITT analysis to under-
estimate the true treatment effect of enzalutamide on OS.
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OBJECTIVES: In the last 3 years, many new advanced melanoma treatments have 
come to market. Ipilimumab was the first compound to demonstrate a statistically 
significant improvement in overall survival in two Phase III RCTs and observational 
studies, with prolonged long-term survival up to 10 years. METHODS: Data from 
the advanced melanoma trials: CA184-024, MDX010-20 and BRIM-3 were used to 
develop an economic model in the UK and to predict the conditional survival of 
patients treated with ipilimumab, dacarbazine and vemurafenib who survived 2 
years. Dabrafenib, pembrolizumab and nivolumab were not valid UK comparators. The 
model uses patient level Kaplan–Meier data for the first 2 years for ipilimumab and 
dacarbazine, gompertz parametric curves fitted to patient level data from 2 to 5 years, 
and American Joint Committee on Cancer registry data from 5 years to 40 years. The 
curves were a good fit to the trial data and consistent with published longer-term data 
for ipilimumab (up to 10 years). Vemurafenib data were taken from the Roche submis-
sion to NICE, with covariate adjustment to account for differences in patient charac-
teristics between trials: M-stage, brain metastases, LDH, gender and ECOG. RESULTS: 
Once a previously untreated patient has survived 2 years, the modelled probability 
of being alive at 5 years is 70.9% for ipilimumab, 44.3% for dacarbazine and 50.2% for 
vemurafenib. At 10 years conditional survival is 45.4%, 28.4% and 31.6%, respectively; 
at 20 years 19.2%, 12.0% and 12.9%. Difference in mean survival was 1.2 years vs dac-
arbazine; 0.4 vs vemurafenib. CONCLUSIONS: A substantial proportion of patients 
treated with ipilimumab surviving to 2 years are likely to have a sustained survival 
benefit: 45.4% of such ipilimumab patients are alive at 10 years and 19.2% at 20 years. 
The level of sustained survival is lower with dacarbazine and vemurafenib.
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OBJECTIVES: NCCN guidelines recommend a serotonin-3 receptor antagonist 
(5-HT3-RA), a substance P/neurokinin 1 (NK1) receptor antagonist, and dexametha-
sone for patients undergoing highly emetogenic chemotherapy (HEC) for the preven-
tion of chemotherapy-induced nausea and vomiting (CINV). This same combination 
is also recommended in patients using moderately emetogenic chemotherapy (MEC) 
at higher risk for CINV. This study estimated the budget impact of adopting netupi-
tant/palonosetron (NEPA), an oral fixed-dose combination of a 5-HT3-RA and an NK1 
for antiemetic prophylaxis, from a U.S. health plan perspective. METHODS: A deci-
sion analytic model compared treatment costs before and after adoption of NEPA 
